Prestige Consumer Healthcare Stock - Analyst consensus and valuation snapshot

Prestige Consumer Healthcare stock draws interest from retail investors as analyst targets, earnings expectations and valuation metrics frame the risk-reward profile. A look at consensus, profitability and balance sheet strength gives structure to the current market view.

Edited by ad hoc news Analyst & Consensus Desk. Verified prior to publication on 06/18/2026, 19:38 CET. Details in the imprint.

Prestige Consumer Healthcare (US74116D1037) sits firmly in the US mid-cap consumer health space with a portfolio of over-the-counter brands and household products. With no fresh company-specific headlines today from major wires or investor relations, the stock is mainly guided by existing analyst estimates and valuation marks.

What consensus estimates show

Prestige Consumer Healthcare stock is followed by a relatively small analyst group, with MarketWatch data showing several covering brokers and a consensus rating in the broad Hold-to-Buy range. Target prices published in recent months cluster moderately above the current quote, implying limited but positive expected upside.

Consensus models project steady low-single-digit to mid-single-digit revenue growth over the next few fiscal years, underpinned by stable demand in over-the-counter healthcare and household categories. Earnings-per-share estimates generally reflect margin resilience helped by prior pricing actions and cost control, albeit without aggressive growth assumptions.

How the market values the stock

On standard valuation metrics, Prestige Consumer Healthcare trades at a forward price-earnings multiple in the low- to mid-teens, broadly in line with or slightly below many branded consumer-health peers according to data compiled by MarketWatch. That multiple embeds expectations for modest growth rather than a high-growth profile.

Free cash flow generation has been a consistent feature of the business, with recent years showing robust cash conversion that supports balance-sheet de-leveraging and potential capital allocation flexibility. Net debt remains meaningful after past acquisitions, but management has emphasized disciplined leverage reduction in presentations and filings.

The product behind the stock

Prestige Consumer Healthcare generates revenue primarily from over-the-counter health and personal care brands, including well-known names such as the feminine hygiene product line Summer’s Eve and various analgesic, digestive care and household cleaning products. The company focuses on mature but defensible categories with steady consumer demand.

Where the stock trades today

Prestige Consumer Healthcare shares (US74116D1037) trade on the New York Stock Exchange at around $68.50 as of 06/18/2026, 11:30 EST.

Key facts on Prestige Consumer Healthcare stock

• Company: Prestige Consumer Healthcare Inc.
• ISIN: US74116D1037
• WKN: A2DJLZ
• Ticker: PBH
• Venue: NYSE
• Price (as of 06/18/2026, 11:30 EST): 68.50 USD
• Market cap: 3,400,000,000 USD (as of 06/18/2026)
• Sector / Industry: Consumer Staples / Personal Products
• Index membership: not a member of the S&P 500 or Nasdaq-100
• Next earnings date: not officially scheduled

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.